Alkermes Investigational Site
Chula Vista, California, 91911, United States
NCT Number: NCT02922426
This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
Looking for future studies?
Notify Me18 year–40 year
All sexes
Interventional
Phase 1
Chula Vista, California, 91911, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily dosing for 21 consecutive days
Daily dosing for 21 consecutive days
Daily dosing for 21 consecutive days
Time frame: 21 days
Differences will be compared among treatment groups
Time frame: 21 days
Differences will be compared among treatment groups
Time frame: 24 days
Alkermes, Inc.
Industry
A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07422298
Healthy Volunteers
San Antonio, Texas, United States
View Trial DetailsNCT07215299
Healthy Volunteers
Bloomington, Indiana, United States
View Trial DetailsNCT03113903
Anxiety Disorders, Behavior
Clermont-Ferrand, France
View Trial DetailsNCT07742137
Aging, Behavior
Seville, Spain
View Trial Details